Skip to content

PP620fcg-01

Exploratory Study on the Safety of Bone Grafting Using PP620fcg and Autogenous Bone in Patients Undergoing Maxillary and Mandibular Osteotomy for Jaw Deformity - PP620fcg-01

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2032260235
Enrollment
6
Registered
2026-06-22
Start date
2026-06-12
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Jaw Abnormalities Jaw Abnormalities

Interventions

A mandibular graft is performed according to the extent of the maxillary bone defect. For bone fragments that cannot be firm ly secured with plates, PP620fcg gel is applied to the grafted bone fragmen

Sponsors

Sakamoto Yoshiaki
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients with malocclusion, determined by the principal or s ub-investigator to require maxillary and mandibular osteotomy for surgical correction. 2.Patients who need bone grafting with a maxillary movement of 3 mm or more. 3.Aged between 18 and 40 years. 4.Patients who provided informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1.Patients with sinusitis. 2.Patients with concurrent or previous malignant tumors. 3.Patients with a history of radiation therapy for malignant tu mors in the oral or surrounding areas. 4.Patients with sepsis or suspected sepsis. 5.Patients with a history of central nervous system, liver, kidn ey, heart, or blood disorders, where the principal or sub-invest igator judges the trial poses safety risks. 6.Patients with severe collagen disease, hormone metabolism abnormalities targeting bones, immunodeficiency, metabolic d isorders, or endocrine disorders. 7.Patients with severe mental or neurological disorders. 8.Patients who have been on bisphosphonates for more than three months prior to consent, or on denosumab for more tha n six months prior to consent, and are unable to discontinue d uring the trial period. 9.Patients with a history of severe drug allergies. 10.Patients who are pregnant, possibly pregnant, or breastfee ding, and are unable to agree to medically appropriate contrac eption during the trial period. 11.Other patients deemed unsuitable by the principal or sub-i nvestigator.

Design outcomes

Primary

MeasureTime frame
Safety: 1. Adverse events and malfunctions that cannot be ruled out as causally related to PP620fcg

Contacts

Public ContactIkkei Tamada

Tokyo Metropolitan Children's Medical Center

ikkei_tamada@tmhp.jp+81-42-300-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026